Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Nov 4, 2024 (2 years ago)

ZapMax Capsules

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Cause type: Chemical / undeclared

A chemical that should not be there - benzene, methanol, lead - or an undeclared prescription drug hidden in a supplement. The label gives no warning: you may be taking a toxic solvent, a heavy metal, or a drug such as sildenafil that interacts with your other medicines. All chemical / undeclared recalls.

What was recalled

ZapMax Capsules, 500 mg, 10 count blisters in cartons, Distributed by: ZapMax, 2108 N St. Sacramento, CA 95816, www.zapmax.com

Recalling firm
Boulla LLC
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Nov 4, 2024 · FDA notice with lot numbers
FDA recall number
D-0086-2025 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other recalls by Boulla LLC

All 2024 recalls
Class I · High risk

ZoomMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0085-2025
Class I · High risk

PeakMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0084-2025
Class I · High risk

VitalityXtra Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0083-2025

Other chemical / undeclared recalls from 2024

All chemical / undeclared recalls
Class II · Moderate risk

Umary Acid Hyaluronic

cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.

Ongoing Chemical / undeclared Mxbbb D-0166-2025